DOCSLIB.ORG

Alice Seywright Bsc (Hons) Msc MRSC

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Synthetic Cannabinoid Receptor Agonists in Scottish Sub-Populations Thesis Submitted in Accordance with the Requirements of the University of Glasgow for the Degree of Doctor of Philosophy By Alice Seywright BSc (Hons) MSc MRSC Forensic Medicine and Science (School of Medicine, Dentistry and Nursing) March 2020 Acknowledgements Thanks, first and foremost, must go to my supervisors, Dr. Hazel Torrance and Dr. Fiona Wylie, for their help, guidance and support in conducting this research, obtaining samples and reviewing this thesis. The input from Denise McKeown was invaluable to the method development aspect of this work and my great thanks go also to her for this, and her general support. I would not have the opportunity to undertake this PhD were it not for Dr. Gail Cooper, who not only supported me through my MSc, but invited me back to the department of Forensic Medicine and Science to work and conduct this research. It is entirely possible I would have binned my work and given up entirely if it wasn’t for the fact that Lauren O’Connor was more often than not experiencing the same frustrations and challenges as I was. Thanks to Lauren for listening to my rants and for all her help and support throughout this… ordeal journey. Thanks also to Claire Parks for all her technical support, tending to QTrap1, and generally keeping me sane over the past few years. I genuinely would not have been able to complete this PhD without Fraser, most likely as I would have succumbed to hunger and rage. My dinner was always on the table when I got in; he has given hours of his life to proof reading and my practice presentations; and his overall support was immense. He certainly knows much more about SCRAs than the average Maths Teacher. Thank you. For general and miscellaneous advice and support, you cannot get much better than my dad, Ian, and mother-in-law Lindsay. They know where a semi-colon goes and exactly what word it is I know exists but cannot immediately place. My dad has also had the unenviable task of raising me in less than ideal circumstances and I owe him more than just thanks. No acknowledgements section is complete without mention of Tchai and Edinson. Their resigned acceptance of hugs, endured without struggle or scratching, got me through many a bad day of failed extractions and instrument breakdowns. i “Were there none who were discontented with what they have, the world would never reach anything better.” – Florence Nightingale “Life shrinks and expands in proportion to one’s courage” – Anaïs Nin ii Author’s Declaration “I declare that, except where explicit reference is made to the contribution of others, that this thesis is the result of my own work and has not been submitted for any other degree at the University of Glasgow or any other institution” Signature _______________________________ Printed name _______________________________ iii Table of Contents 1. Introduction ....................................................................................................... 1 1.1. Background ...................................................................................................... 1 1.2. Cannabinoid Receptors .................................................................................... 1 1.3. Phytocannabinoids ........................................................................................... 2 1.4. Endocannabinoids ............................................................................................ 3 1.5. Synthetic Cannabinoid Receptor Agonists ....................................................... 4 1.5.1. Chemistry and Nomenclature .................................................................. 14 1.5.2. Pharmacology .......................................................................................... 17 1.5.3. Prevalence and Risk of Harm .................................................................. 20 1.5.4. Analysis in Biological Matrices ................................................................. 23 2. Aims and Objectives ....................................................................................... 29 3. Development and Validation of a Method for the Detection and Quantitation of MDMB-CHMICA in Blood ...................................................................................... 30 3.1. Introduction ..................................................................................................... 30 3.2. Aims and Objectives ....................................................................................... 31 3.3. Materials ......................................................................................................... 31 3.3.1. Solutions .................................................................................................. 31 3.4. Method Development and Optimisation.......................................................... 34 3.4.1. Liquid Chromatography – Mass Spectrometry ......................................... 34 3.4.2. Extraction ................................................................................................. 35 3.4.3. Method Validation .................................................................................... 36 3.5. Results and Discussion .................................................................................. 38 3.5.1. Liquid-Chromatography – Mass Spectrometry ......................................... 38 3.5.2. Method Validation .................................................................................... 41 3.6. Conclusion ...................................................................................................... 50 4. Development and Validation of a Method for the Detection and Quantitation of Synthetic Cannabinoid Receptor Agonists in Blood and Urine ............................. 51 4.1. Aims and Objectives ....................................................................................... 51 iv 4.2. Materials ......................................................................................................... 51 4.3. Method ........................................................................................................... 52 4.3.1. Solutions .................................................................................................. 52 4.3.2. Selection of Analytes ............................................................................... 55 4.3.3. Liquid Chromatography – Mass Spectrometry ......................................... 56 4.3.4. Extraction of Analytes .............................................................................. 57 4.3.5. Method Validation – Blood ....................................................................... 62 4.3.6. Method Validation – Urine ........................................................................ 64 4.3.7. Validation – Intermediate Methods .......................................................... 65 4.3.8. Comparison of Prison ‘A’ and ‘B’ Samples ............................................... 66 4.3.9. Analysis of Drug Packets ......................................................................... 67 4.4. Results and Discussion .................................................................................. 70 4.4.1. Selection of Analytes ............................................................................... 70 4.4.2. Liquid Chromatography – Mass Spectrometry ......................................... 88 4.4.3. Extraction of Analytes ............................................................................ 103 4.4.4. Method Validation – Method 2.1 applied to blood .................................. 115 4.4.5. Method Validation – Methods 1.1, 1.2 and 2.1 applied to urine ............. 134 4.4.6. Comparison of Prison ‘A’ and ‘B’ Samples ............................................. 149 4.4.7. Analysis of Drug Packets ....................................................................... 152 4.5. Conclusion .................................................................................................... 153 5. Synthetic Cannabinoid Receptor Agonists in Scottish Sub-Populations ....... 155 5.1. Summary ...................................................................................................... 155 5.2. Individuals Undergoing Emergency Department Treatment ......................... 159 5.2.1. Introduction ............................................................................................ 159 5.2.2. Method ................................................................................................... 159 5.2.3. Results and Discussion.......................................................................... 160 5.2.4. Conclusion ............................................................................................. 177 5.3. Post-Mortem Casework ................................................................................ 178 5.3.1. Introduction ............................................................................................ 178 v 5.3.2. Method ................................................................................................... 178 5.3.3. Results and Discussion.......................................................................... 179 5.3.4. Conclusions ........................................................................................... 195 5.4. Individuals Admitted to or Liberated From a Scottish Prison Service Facility197 5.4.1. Introduction ...........................................................................................
Recommended publications
  • Report of the Advisory Group to Recommend Priorities for the IARC Monographs During 2020–2024

    Report of the Advisory Group to Recommend Priorities for the IARC Monographs During 2020–2024

    IARC Monographs on the Identification of Carcinogenic Hazards to Humans Report of the Advisory Group to Recommend Priorities for the IARC Monographs during 2020–2024 Report of the Advisory Group to Recommend Priorities for the IARC Monographs during 2020–2024 CONTENTS Introduction ................................................................................................................................... 1 Acetaldehyde (CAS No. 75-07-0) ................................................................................................. 3 Acrolein (CAS No. 107-02-8) ....................................................................................................... 4 Acrylamide (CAS No. 79-06-1) .................................................................................................... 5 Acrylonitrile (CAS No. 107-13-1) ................................................................................................ 6 Aflatoxins (CAS No. 1402-68-2) .................................................................................................. 8 Air pollutants and underlying mechanisms for breast cancer ....................................................... 9 Airborne gram-negative bacterial endotoxins ............................................................................. 10 Alachlor (chloroacetanilide herbicide) (CAS No. 15972-60-8) .................................................. 10 Aluminium (CAS No. 7429-90-5) .............................................................................................. 11
  • Monoazo Dyes of the Benzothiazole Series, Their Preparation and Use In

    Monoazo Dyes of the Benzothiazole Series, Their Preparation and Use In

    Europâisches Patentamt 0 013 809 (ij) QJJJ EuropeanEurooean Patent Office Qj)l'ï> Publication number: V ^- Office européen des brevets (lD EUROPEAN PATENT SPECIFICATION © Date of publication of patent spécification: 10.08.83 © Int. Cl.3: C 09 B 23/00, C 09 B 29/08, D 06 P 1/18 @^ Application number: 79302860.6 @ Dateof filing: 12.12.79 54) Monoazo dyes of the benzothiazole séries, their préparation and use in dyeing or printing hydrophobic fibres. (30) Priority: 25.12.78 JP 163617/78 @ Proprietor: SUMITOMO CHEMICAL COMPANY, 03.10.79 JP 128308/79 LIMITED 1 5 Kitahama 5-chome Higashi-ku Osaka-shi Osaka-fu (JP) © Date of publication of application: 06.08.80 Bulletin 80/16 @ Inventor: Yoshinaga, Kenja 10-3-314, Sonehigashinocho-2-chome @ Publication of the grant of the patent: Tokonaka-shi (JP) 1 0.08.83 Bulletin 83/32 Inventor: Hashimoto, Kiyoyasu 2-40, Hirata-1-chome Ibaraki-shi (JP) (84) Designated Contracting States: Inventor: Okaniwa, Tetsuo CH DE FR GB IT NL 27, Kuisehonmachi-1 -chome Amagasaki-shi (JP) Inventor: Kenmochi, Hirohito @ References cited: 9-1 5, Matsugaoka-4-chome DE - A - 1 959 777 Takatsuki-shi (JP) FR - A - 1 444 036 GB - A - 944 250 GB - A - 1 448 782 @ Representative: Harrison, Michael Robert et al, Urquhart-Dykes & Lord 47 Marylebone Lane London W1 M 6DL(GB) The file contains technical information submitted after the application was filed and not included in this specification Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
  • The Mechanism of Pyridine Hydrogenolysis on Molybdenum-Containing Catalysts III

    The Mechanism of Pyridine Hydrogenolysis on Molybdenum-Containing Catalysts III

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Universiteit Twente Repository JOURNAL OF CATALYSIS 34, 215-229 (1974) The Mechanism of Pyridine Hydrogenolysis on Molybdenum-Containing Catalysts III. Cracking, Hydrocracking, Dehydrogenation and Disproportionation of Pentylamine J. SONNEMANS” AND P. MARS l’wente University of Technology, Enschede, The Netherlands Received October 30, 1973 The conversion of pentylamine on a MoOrA1203 catalyst was studied between 250 and 350°C at various hydrogen pressures. The reactions observed were cracking to pentene and ammonia, hydrocracking to pentane and ammonia, dehydrogenation to pentanimine and butylcarbonitrile, and disproportionation to ammonia and dipentylamine. The equilibrium between pentylamine, dipentylamine and ammonia appeared to be established under most of the experimental conditions. The equilibrium constant is about 9 at 250°C and about 5 at 320°C. The disproportionation reaction is zero order in hydrogen and of -1 order in the initial pentylamine pressure. Dehydrogenation was observed at low hydrogen pressures, and especially at higher temperatures; the reaction is first order in pentylamine. Both cracking and hydrocracking take place, mainly above 300°C. Hydrocracking appears to be half order in hydrogen; the rate of cracking is almost independent of the hydrogen pressure. The hydrocarbon formation is of zero order in pentyl- amine or dipentylamine. The same type of reactions (except hydrocracking) take place on alumina, but with a far lower reaction rate. INTRODUCTION catalysts at hydrogen pressures of about One of the intermediates formed in the 60 atm (Z-4). They reported a high rate hydrogenolysis of pyridine is pentylamine of ammonia formation from the primary (1).
  • Method for Producing Pyridine Compound

    Method for Producing Pyridine Compound

    (19) TZZ¥_¥¥_T (11) EP 3 159 339 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 153(4) EPC (43) Date of publication: (51) Int Cl.: 26.04.2017 Bulletin 2017/17 C07D 413/04 (2006.01) C07D 471/04 (2006.01) A01N 43/76 (2006.01) A01N 43/90 (2006.01) (21) Application number: 15806287.7 (86) International application number: (22) Date of filing: 29.05.2015 PCT/JP2015/065512 (87) International publication number: WO 2015/190316 (17.12.2015 Gazette 2015/50) (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • WAKAMATSU, Takayuki GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Oita-shi PL PT RO RS SE SI SK SM TR Oita 870-0106 (JP) Designated Extension States: • KASAI, Rika BA ME Osaka-shi Designated Validation States: Osaka 554-8558 (JP) MA (74) Representative: Vossius & Partner (30) Priority: 09.06.2014 JP 2014118457 Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 (71) Applicant: Sumitomo Chemical Company, Limited 81675 München (DE) Tokyo 104-8260 (JP) (54) METHOD FOR PRODUCING PYRIDINE COMPOUND (57) To make it possible to produce a pyridine compound represented by formula (1) that is useful as an insecticide by reacting a compound represented by formula. (2) and a compound represented by formula (3). (In the formula, 1L represents a halogen atom; R2, R3, R4, R5, and R6 represent chain hydrocarbon groups, etc., having 1-6 carbon atoms optionally substituted by fluorine atoms. A 1 represents-NR7-, an oxygen atom, or a sulfur atom; A 2 represents a nitrogen atom or =CR8-.
  • Hydrophobically Modified Polyethyleneimines And

    Hydrophobically Modified Polyethyleneimines And

    Wright State University CORE Scholar Browse all Theses and Dissertations Theses and Dissertations 2007 Hydrophobically Modified olyP ethyleneimines and Ethoxylated Polyethyleneimines Michael Joseph Simons Wright State University Follow this and additional works at: https://corescholar.libraries.wright.edu/etd_all Part of the Chemistry Commons Repository Citation Simons, Michael Joseph, "Hydrophobically Modified olyP ethyleneimines and Ethoxylated Polyethyleneimines" (2007). Browse all Theses and Dissertations. 162. https://corescholar.libraries.wright.edu/etd_all/162 This Thesis is brought to you for free and open access by the Theses and Dissertations at CORE Scholar. It has been accepted for inclusion in Browse all Theses and Dissertations by an authorized administrator of CORE Scholar. For more information, please contact [email protected]. Hydrophobically Modified Polyethyleneimines and Ethoxylated Polyethyleneimines A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science By MICHAEL J. SIMONS B.A., Columbia University, 1985 2007 Wright State University Wright State University School of Graduate Studies August 8, 2007 I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY SUPERVISION BY Michael J. Simons ENTITLED Hydrophobically Modified Polyethyleneimines and Ethoxylated Polyethyleneimines BE ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF Master of Science. _______________________________ Eric Fossum, Ph. D. Thesis Director _______________________________ Kenneth Turnbull, Ph.D. Department Chair Committee on Final Examination _______________________________ Eric Fossum, Ph. D. _______________________________ Daniel Ketcha, Ph. D. _______________________________ Kenneth Turnbull, Ph.D. _______________________________ Joseph F. Thomas, Jr. Ph.D. Dean, School of Graduate Studies Abstract Michael Simons. M.S., Department of Chemistry, Wright State University, 2007. Hydrophobically Modified Polyethyleneimines and Ethoxylated Polyethyleneimines.
  • United States Patent Office

    United States Patent Office

    3,252,929 United States Patent Office Patented May 24, 1966 2 been prepared by hydrolyzing triethyltin halides with 3,252,929 aqueous alkali and dehydrating the resulting product at HEAT AND LIGHT STABLE HALOGEN-CONTAIN NG RESNS STABLIZED BY TRALKYL TN elevated temperatures; it has also been produced by dis PROPOLATES tilling triethyltin hydroxide under reduced pressure, by Ferdinand C. Mieyer, St. Louis, Mo., assignor to Monsanto reacting silver oxide with S-methyl triethyltin or bis(tri Company, a corporation of Delaware ethyltin) sulfide, and by reacting triethyltin hydride with No Drawing. Filed Dec. 28, 1961, Ser. No. 162,925 metal oxides such as HgC), ZnO, Fe2O3, PbO, AS4O6, 13 Claims. (C. 260-23) VO5 and KMnO4. Bis(trihexyltin) oxide has been pre pared by shaking trihexyltin bromide with aqueous This invention relates to the stabilization of halogen O sodium hydroxide in ether. Bis(trioctyltin) oxide has containing resins against the deteriorating effects of heat been prepared in a similar manner by brominating tet and light. raooctyltin at -40° C., shaking the resulting trioctyltin Halogen-containing resin polymers are notoriously un bromide with aqueous 33% sodium hydroxide in ether, stable upon exposure to heat and ultraviolet light. This and drying the product after removal of the Solvent at instability is evidenced by the rapid discoloration and 15 100° C./12 mm. The higher bis(trialkyltin) oxide may Serious stiffening apparent after exposure to processing be prepared by similar methods. temperatures, and/or outdoor weathering. Moreover, The propiolic acid used in the reaction with the bis(tri this instability is sometime aggravated by the presence alkyltin) oxides to produce trialkyltin propiolates is a of plasticizers and other additives which are themselves well known, readily available material.
  • Text Related to Segment 4.04 ©2002 Claude E. Wintner to Elaborate On

    Text Related to Segment 4.04 ©2002 Claude E. Wintner to Elaborate On

    Text Related to Segment 4.04 ©2002 Claude E. Wintner To elaborate on the ideas developed so far, let us work out in some detail the cases of those C8H18 hydrocarbons that contain a stereogenic center or centers. Considering first only constitution, of the eighteen different constitutional formulae possible in the C8H18 manifold, in just five of these does one find a stereogenic carbon atom or atoms, substituted with four constitutionally distinct ligands, and marked in the figure by a dot. In those four cases where there is only a single stereogenic center, the situation is precisely the same as for 3-methylhexane. Each of these four constitutional formulae represents an enantiomeric pair, that is, two configurational isomers differing in their configuration at the stereogenic carbon atom. One isomer will have R absolute configuration, and the other S. H 2,3-dimethylhexane H 3-methylheptane H 2,4-dimethylhexane H 2,2,3-trimethylpentane H 3,4-dimethylhexane H the five constitutional isomers (among eighteen total) having molecular formula C8H18 that contain a stereogenic center or centers On the other hand, the case with two stereogenic centers, 3,4- dimethylhexane, presents a particularly instructive example and will lead us once again onto some new ground. A special symmetry in the molecule is apparent: each of the two stereogenic centers is identically substituted — from the point of view of constitution — by hydrogen, a methyl group, an ethyl group, and a secondary butyl group. In the next segment we shall see that there exist three molecules, all three having the constitution 3,4-dimethylhexane, but each one differing from the other two in its configuration.
  • Stable Strontium Angew

    Stable Strontium Angew

    research highlights METAL ALKYL COMPLEXES Stable strontium Angew. Chem. Int. Ed. https://go.nature.com/2Nugrmp (2019). Et Et Et Ar Ar Ar H N Et Sr[N(SiMe ) ] N N N 3 2 2 PhSiH3 Sr N(SiMe3)2 Sr Sr NH Et N N N Et H Ar Ar Ar 1 2 Et Et Ar Ar Et N N Ethylene polymerization, Sr Sr nucleophilic aromatic N N substitution Et Ethylene Ar Ar Ar Ar H N N 3 Sr Sr N N H Ar Ar 2 D Ar Ar 2 D N N HD– isotope exchange Sr Sr N N D Ar Ar 4 Metal alkyls have a prominent place was not just the result of ligand size, but in organic synthesis. For instance, also due to agostic interactions between Sr organomagnesium and organolithium and the C–H bond in the 3-pentyl group. compounds are among the first choices Addition of PhSiH3 produced the strontium for carbon nucleophiles and bases, as hydride dimer (complex 2), which is also well as taking part in catalytic reactions stable and soluble in apolar solvents. such as the Kumada coupling. But, as you go With this complex in hand the team further down groups 1 and 2 in the periodic could explore its chemistry. The hydride table, the corresponding metal alkyls dimer engaged in H–D isotope exchange become more unstable or, in many cases, in C6D6 solution (leading to the production have not even been isolated. It is only in of deuterated analogue 4), and acted as recent years that unstabilized alkyl–calcium a catalyst for benzene deuteration with compounds have been prepared, by the D2.
  • NIH Public Access Author Manuscript Bioorg Med Chem Lett

    NIH Public Access Author Manuscript Bioorg Med Chem Lett

    NIH Public Access Author Manuscript Bioorg Med Chem Lett. Author manuscript; available in PMC 2013 September 15. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Bioorg Med Chem Lett. 2012 September 15; 22(18): 5889–5892. doi:10.1016/j.bmcl.2012.07.074. Biologically Active Ester Derivatives as Potent Inhibitors of the Soluble Epoxide Hydrolase In-Hae Kima,b, Kosuke Nishia,b, Takeo Kasagamia,c, Christophe Morisseaua, Jun-Yan Liua, Hsing-Ju Tsaia, and Bruce D. Hammocka,* aDepartment of Entomology and UC Davis Comprehensive Cancer Center, University of California, One Shields Avenue, Davis, California 95616, USA Abstract Substituted ureas with a carboxylic acid ester as a secondary pharmacophore are potent soluble epoxide hydrolase (sEH) inhibitors. Although the ester substituent imparts better physical properties, such compounds are quickly metabolized to the corresponding less potent acids. Toward producing biologically active ester compounds, a series of esters were prepared and evaluated for potency on the human enzyme, stability in human liver microsomes, and physical properties. Modifications around the ester function enhanced in vitro metabolic stability of the ester inhibitors up to 32-fold without a decrease in inhibition potency. Further, several compounds had improved physical properties. Keywords sEH; sEH inhibitors; substituted urea-ester derivatives; metabolic stability Epoxyeicosatrienoic acids (EETs), which are metabolites of arachidonic acid by cytochrome P450 epoxygenases,
  • Herbicidal Composition

    Herbicidal Composition

    Europaisches Patentamt (19) European Patent Office Office europeeneen des brevets EP 0 901 752 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) intci.6: A01N 37/18, A01N 37/20, 17.03.1999 Bulletin 1999/11 A01N 37/22, A01N 43/10, A01 N 43/36, A01 N 43/40 (21) Application number: 98307102.8 (22) Date of filing: 03.09.1998 (84) Designated Contracting States: • Kitajima, Toshio, Tokuyama Corporation AT BE CH CY DE DK ES Fl FR GB GR IE IT LI LU Tokuyama-shi, Yamaguchi-ken 745-0053 (JP) MC NL PT SE • Koyanagi, Shinichiro, Tokuyama Corporation Designated Extension States: Tokuyama-shi, Yamaguchi-ken 745-0053 (JP) AL LT LV MK RO SI (74) Representative: Sexton, Jane Helen (30) Priority: 03.09.1997 JP 238710/97 J.A. KEMP & CO. 14 South Square (71) Applicant: TOKUYAMA CORPORATION Gray's Inn Tokuyama-shi, Yamaguchi-ken 745-0053 (JP) London WC1R 5LX (GB) (72) Inventors: • Fukada, Noriyuki, Tokuyama Corporation Tokuyama-shi, Yamaguchi-ken 745-0053 (JP) (54) Herbicidal composition (57) A herbicidal composition containing an etheny- lamide compound as a herbicidally effective component and a dichloroacetamide compound as a safener. CM O O) o a. LU Printed by Jouve, 75001 PARIS (FR) EP 0 901 752 A1 Description [0001] The present invention relates to a herbicidal composition comprising an ethenylamide compound and a dichlo- roacetamide compound. [0002] It is known that ethenylamide compounds have excellent herbicidal activity against the weeds of the grass family (JP-B 5-1 5699) (the term "JP-B" as used herein means an "examined Japanese patent publication").
  • (12) United States Patent (10) Patent No.: US 9,466,839 B2 Otsuka Et Al

    (12) United States Patent (10) Patent No.: US 9,466,839 B2 Otsuka Et Al

    USOO946,6839B2 (12) United States Patent (10) Patent No.: US 9,466,839 B2 Otsuka et al. (45) Date of Patent: *Oct. 11, 2016 (54) ELECTRODE ACTIVE MATERIAL FOR (52) U.S. Cl. ELECTRICITY STORAGE DEVICE, AND CPC ............... H01 M 4/60 (2013.01): HOIG II/30 ELECTRICITY STORAGE DEVICE USING (2013.01); HOIG II/48 (2013.01); H0IG SAME II/50 (2013.01); (Continued) (75) Inventors: Yu Otsuka, Osaka (JP); Nobuhiko (58) Field of Classification Search Hojo, Osaka (JP): Takafumi CPC ................................................. HO1M 1070525 Tsukagoshi, Osaka (JP); Toshiki See application file for complete search history. Nokami, Kyoto (JP); Jun-ichi Yoshida, Kyoto (JP) (56) References Cited (73) Assignee: Panasonic Corporation, Osaka (JP) U.S. PATENT DOCUMENTS 4,343,871 A 8, 1982 Tobishima et al. (*) Notice: Subject to any disclaimer, the term of this 5,143,805 A * 9/1992 Anderman .............. HO1M 2/14 patent is extended or adjusted under 35 429,217 U.S.C. 154(b) by 964 days. (Continued) This patent is Subject to a terminal dis claimer. FOREIGN PATENT DOCUMENTS EP O 911 893 A1 4f1999 (21) Appl. No.: 13/583,880 EP 1406339 A1 4/2004 (22) PCT Filed: Mar. 11, 2011 (Continued) (86). PCT No.: OTHER PUBLICATIONS S 371 (c)(1), JP 2008222559 A Translation from Espacenet.* (2), (4) Date: Sep. 10, 2012 (Continued) (87) PCT Pub. No.: WO2011/111401 Primary Examiner — Barbara Gilliam PCT Pub. Date: Sep. 15, 2011 Assistant Examiner —Nathanael Zemui (74) Attorney, Agent, or Firm — McDermott Will & (65) Prior Publication Data Emery LLP US 2013 FOOO483.6 A1 Jan. 3, 2013 (57) ABSTRACT The present invention provides an electrode active material (30) Foreign Application Priority Data for an electricity storage device, having a structure repre sented by following formula (1).
  • Annex XV Report

    Annex XV Report

    Substance Name: 2-(2H-benzotriazol-2- yl)-4-(tert-butyl)-6-(sec-butyl)phenol (UV-350) EC Number: 253-037-1 CAS Number: 36437-37-3 SUPPORT DOCUMENT FOR IDENTIFICATION OF 2-(2H-BENZOTRIAZOL-2-YL)-4-(TERT- BUTYL)-6-(SEC-BUTYL)PHENOL (UV-350) AS A SUBSTANCE OF VERY HIGH CONCERN BECAUSE OF ITS VPVB (ARTICLE 57 E) PROPERTIES SVHC SUPPORT DOCUMENT - UV-350 CONTENTS PROPOSAL FOR IDENTIFICATION OF A SUBSTANCE OF VERY HIGH CONCERN ON THE BASIS OF THE CRITERIA SET OUT IN REACH ARTICLE 57 ..........................................................10 PART I ................................................................................................................ ERROR! BOOKMARK NOT DEFINED. JUSTIFICATION ................................................................................................................................................12 1. IDENTITY OF THE SUBSTANCE AND PHYSICAL AND CHEMICAL PROPERTIES ............12 1.1. Name and other identifiers of the substance ..................................................................................... 12 1.2. Composition of the substance .................................................................................................................. 13 1.3. Identity and composition of structurally related substances (used in a grouping or read-across approach) ................................................................................................................. 14 1.4. Physicochemical properties ......................................................................................................................